All Stories

  1. Spinal cord stimulation therapy for gait impairment in Parkinson’s disease: a double-blinded, randomised feasibility trial with an open extension
  2. Hemispheric lateralization of dopamine transporter binding in Parkinson's disease
  3. Depression preceding and following the diagnosis of Parkinson’s disease and Lewy body dementia
  4. Myocardial sympathetic distal axon loss in subjects with Lewy pathology: an artificial intelligence‐based histopathological analysis
  5. Idiopathic polyneuropathy with neurogenic autonomic failure – an early manifestation of Lewy body disease? a case report
  6. Estrogen-related receptor gene expression associates with sex differences in cortical atrophy in isolated REM sleep behavior disorder
  7. Inter-relationship of the age of onset to the concept of brain-first versus body-first Parkinson's disease
  8. Myocardial sympathetic distal axon loss in subjects with Lewy pathology in three autopsy cohorts
  9. Trusting Your Gut When it Comes to the Origin of Parkinson's Disease
  10. Distinct brain atrophy progression subtypes underlie phenoconversion in isolated REM sleep behaviour disorder
  11. Cholinergic patterns correlate with dopamine medication ON freezing of gait in Parkinson’s disease
  12. Impaired sleep microarchitecture is associated with locus coeruleus degeneration in Parkinson’s disease
  13. Comparison of Deuterium Metabolic Imaging with FDG PET in Alzheimer Disease
  14. Sympathetic and parasympathetic subtypes of body-first Lewy body disease observed in postmortem tissue from prediagnostic individuals
  15. The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
  16. Impact of norepinephrine versus phenylephrine on brain circulation, organ blood flow and tissue oxygenation in anaesthetised patients with brain tumours: study protocol for a randomised controlled trial
  17. Bradykinesia and postural instability in a model of prodromal synucleinopathy with α-synuclein aggregation initiated in the gigantocellular nuclei
  18. Nigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms
  19. Validation of a data-driven motion-compensated PET brain image reconstruction algorithm in clinical patients using four radiotracers
  20. Non-motor asymmetry and dopamine degeneration in Parkinson’s disease
  21. Cuneus atrophy and Parkinsonian phenoconversion in cognitively unimpaired patients with isolated REM sleep behavior disorder
  22. Cortical hypometabolism in Parkinson’s disease is linked to cholinergic basal forebrain atrophy
  23. Cholinergic dysfunction in isolated rapid eye movement sleep behaviour disorder links to impending phenoconversion
  24. Correlation between dopaminergic and metabolic asymmetry in Lewy body disease – A dual-imaging study
  25. Approaches to Early Parkinson’s Disease Subtyping
  26. Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”
  27. Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson’s disease
  28. Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same
  29. The Body, the Brain, the Environment, and Parkinson’s Disease
  30. Functional and 123I-MIBG scintigraphy assessment of cardiac adrenergic dysfunction in diabetes
  31. Microglial Activation and Progression of Nigrostriatal Dysfunction in Isolated REM Sleep Behavior Disorder
  32. Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson’s disease
  33. Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes
  34. Brain-first vs. body-first Parkinson's disease: An update on recent evidence
  35. Impaired cholinergic integrity of the colon and pancreas in dementia with Lewy bodies
  36. STING activation counters glioblastoma by vascular alteration and immune surveillance
  37. Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder
  38. Severe cholinergic terminal loss in newly diagnosed dementia with Lewy bodies
  39. Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism
  40. Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson’s Disease
  41. The heterogeneity of Parkinson’s disease
  42. The brain-first vs. body-first model of Parkinson’s disease with comparison to alternative models
  43. Distribution of cholinergic nerve terminals in the aged human brain measured with [18F]FEOBV PET and its correlation with histological data
  44. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases : An [ 11 C ] UCB‐J ...
  45. Thyroid [123I]MIBG uptake in Parkinson’s disease and diabetes mellitus
  46. Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies
  47. Cholinergic Imaging and Dementia
  48. Disruption of Sleep Microarchitecture Is a Sensitive and Early Marker of Parkinson’s Disease
  49. Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study
  50. RBDtector: an open-source software to detect REM sleep without atonia according to visual scoring criteria
  51. Revisiting the Dual-Hit Hypothesis: Insights from Postmortem Studies in Parkinson's Disease
  52. [18F]FEOBV positron emission tomography may not be a suitable method to measure parasympathetic denervation in patients with Parkinson's disease
  53. Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
  54. Imaging progressive peripheral and central dysfunction in isolated REM sleep behaviour disorder after 3 years of follow-up
  55. Spinal cord stimulation therapy for patients with Parkinson’s disease and gait problems (STEP-PD): study protocol for an exploratory, double-blind, randomised, placebo-controlled feasibility trial
  56. Impact of aging on animal models of Parkinson's disease
  57. Intestinal Transit in Early Moderate Parkinson’s Disease Correlates with Probable RBD: Subclinical Esophageal Dysmotility Does Not Correlate
  58. Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
  59. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
  60. In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study
  61. Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches
  62. Passive Immunization in Alpha-Synuclein Preclinical Animal Models
  63. Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
  64. Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
  65. Neuropathological evidence of body-first vs. brain-first Lewy body disease
  66. Long-term Risk of Parkinson Disease Following Influenza and Other Infections
  67. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes
  68. Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson’s Disease: A Longitudinal Analysis of Two International Cohorts
  69. Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy
  70. Radionuclide imaging of the gut-brain axis in Parkinson’s disease
  71. Cortical Activity During an Attack of Ménière's Disease—A Case Report
  72. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease
  73. Vagus Nerve Cross-Sectional Area in Patients With Parkinson's Disease—An Ultrasound Case-Control Study
  74. Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
  75. Fasting gallbladder volume is increased in patients with Parkinson's disease
  76. Preserved noradrenergic function in Parkinson's disease patients with rest tremor
  77. Reduced Synaptic Density in Patients with Lewy Body Dementia: An [ 11 C ] UCB‐J PET Imaging Study
  78. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats
  79. Prodromal Parkinson disease subtypes — key to understanding heterogeneity
  80. Impaired cerebral microcirculation in isolated REM sleep behaviour disorder
  81. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson’s Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline
  82. Asymmetric Distribution of Dopamine Transporters in Premorbid Corticobasal Syndrome—A Case Report
  83. Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
  84. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder
  85. The Logic and Pitfalls of Parkinson's as Brain‐ Versus Body‐First Subtypes
  86. Microsleep disturbances are associated with noradrenergic dysfunction in Parkinson’s disease
  87. Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ
  88. Gastrointestinal Dysfunction in Parkinson’s Disease
  89. Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder
  90. Abstract
  91. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study
  92. Absent 18F-FDG Uptake in the Brain—Unsuspected Brain Death
  93. Skin Temperature in Parkinson’s Disease Measured by Infrared Thermography
  94. Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms
  95. Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study
  96. A Screening-Based Method for Identifying Patients with REM Sleep Behaviour Disorder in a Danish Community Setting
  97. Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers
  98. Applied strategy in the Iowa Gambling Task: Comparison of individuals with Parkinson’s disease to healthy controls
  99. Normative values for gastric motility assessed with the 3D‐transit electromagnetic tracking system
  100. PET Visualized Stimulation of the Vestibular Organ in Menière's Disease
  101. Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
  102. Cholinergic denervation in patients with idiopathic rapid eye movement sleep behaviour disorder
  103. In vivo positron emission tomography imaging of decreased parasympathetic innervation in the gut of vagotomized patients
  104. Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis
  105. Enteric cholinergic neuropathy in patients with diabetes: Non‐invasive assessment with positron emission tomography
  106. Normative values for region‐specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D‐Transit electromagnet tracking system: Influence of age, gender, and body mass index
  107. Positron emission tomography visualized stimulation of the vestibular organ is localized in Heschl's gyrus
  108. 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
  109. Engineered antibodies: new possibilities for brain PET?
  110. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats
  111. 18F-FACBC PET/MRI in Diagnostic Assessment and Neurosurgery of Gliomas
  112. Cardiac 11C-Donepezil Binding Increases With Age in Healthy Humans: Potentially Signifying Sigma-1 Receptor Upregulation
  113. The Gut and Parkinson’s Disease: Hype or Hope?
  114. Imaging the Autonomic Nervous System in Parkinson’s Disease
  115. Evaluation of Active Brown Adipose Tissue by the Use of Hyperpolarized [1-13C]Pyruvate MRI in Mice
  116. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study
  117. Objective intestinal function in patients with idiopathic REM sleep behavior disorder
  118. Is constipation in Parkinson's disease caused by gut or brain pathology?
  119. The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer’s Disease
  120. Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder
  121. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study
  122. Preclinical evaluation of potential infection-imaging probe [68 Ga]Ga-DOTA-K-A9 in sterile and infectious inflammation
  123. Gastrointestinal transit time and heart rate variability in patients with mild acquired brain injury
  124. Gastric emptying in Parkinson's disease – A mini-review
  125. Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients
  126. F26. Automated chin EMG analysis for quantification of REM sleep without atonia
  127. Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm
  128. Molecular Imaging of the Noradrenergic System in Idiopathic Parkinson's Disease
  129. Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study
  130. Multimodal 18 F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma
  131. Tonsillectomy and risk of Parkinson's disease: A danish nationwide population-based cohort study
  132. MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding
  133. Pancreatic Polypeptide in Parkinson’s Disease: A Potential Marker of Parasympathetic Denervation
  134. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study
  135. Noradrenergic Deficits in Parkinson Disease Imaged with 11C-MeNER
  136. How does parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology
  137. Gastrointestinal Transit Time in Parkinson’s Disease Using a Magnetic Tracking System
  138. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease
  139. Objective Colonic Dysfunction is Far more Prevalent than Subjective Constipation in Parkinson’s Disease: A Colon Transit and Volume Study
  140. Preventing Parkinson disease by vagotomy
  141. Imaging Parkinson’s disease below the neck
  142. Reply to the letter to the Editor: Comment to Barichella and colleagues
  143. In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography
  144. Functional image-guided dose escalation in gliomas using of state-of-the-art photon vs. proton therapy
  145. Decreased intestinal acetylcholinesterase in early Parkinson disease
  146. Kinetic Modelling of Infection Tracers [18F]FDG, [68Ga]Ga-Citrate, [11C]Methionine, and [11C]Donepezil in a Porcine Osteomyelitis Model
  147. Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives
  148. Cholinergic PET imaging in infections and inflammation using 11C-donepezil and 18F-FEOBV
  149. Appendectomy and risk of Parkinson's disease: A nationwide cohort study with more than 10 years of follow-up
  150. Constipation and risk of Parkinson’s disease: A Danish population-based cohort study
  151. Vagotomy and subsequent development of diabetes – A nested case–control study
  152. A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis
  153. In vivoimaging of neuromelanin in Parkinson’s disease using18F-AV-1451 PET
  154. Imaging Systemic Dysfunction in Parkinson’s Disease
  155. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
  156. Sex differences of human cortical blood flow and energy metabolism
  157. Does vagotomy reduce the risk of Parkinson's disease: The authors reply
  158. Accuracy of 18F-FDG PET-CT in triaging lung cancer patients with suspected brain metastases for MRI
  159. EANM’15
  160. Reply
  161. Pseudoprogression after proton radiotherapy for pediatric low grade glioma
  162. Spatial distribution of malignant tissue in gliomas: correlations of 11C-L-methionine positron emission tomography and perfusion- and diffusion-weighted magnetic resonance imaging
  163. Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV
  164. Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease
  165. Vagotomy and subsequent risk of Parkinson's disease
  166. Olfactory function in Parkinson's Disease - effects of training
  167. Salivary Acetylcholinesterase Activity Is Increased in Parkinson’s Disease: A Potential Marker of Parasympathetic Dysfunction
  168. Imaging the parasympathetic nervous system in Parkinson's disease
  169. In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using 11C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses
  170. Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders
  171. False-Positive 123I-FP-CIT Scintigraphy and Suggested Dopamine Transporter Upregulation Due to Chronic Modafinil Treatment
  172. Brain Energy Metabolism and Blood Flow Differences in Healthy Aging
  173. Cerebral oxygen metabolism in patients with early Parkinson's disease
  174. Clinical heterogeneity in Parkinson’s disease revisited: a latent profile analysis
  175. Glucose metabolism in small subcortical structures in Parkinson’s disease
  176. Odor identification deficits identify Parkinson's disease patients with poor cognitive performance
  177. The Parkinsonian Personality and Concomitant Depression
  178. Molecular Imaging and the Neuropathologies of Parkinson’s Disease
  179. Variable ATP Yields and Uncoupling of Oxygen Consumption in Human Brain
  180. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensive: probably even at early disease stages
  181. Partial volume correction using cortical surfaces
  182. Age-dependent decline of steady state dopamine storage capacity of human brain: An FDOPA PET study
  183. A deformation-based morphometry study of patients with early-stage Parkinson’s disease
  184. Subcortical elevation of metabolism in Parkinson's disease — A critical reappraisal in the context of global mean normalization
  185. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization
  186. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson’s disease
  187. Low Cerebral Oxygen Consumption and Blood Flow in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy
  188. Improvement of brain tissue oxygenation by inhalation of carbogen
  189. Effect of memantine on CBF and CMRO2in patients with early Parkinson’s disease
  190. Normalization in PET group comparison studies—The importance of a valid reference region
  191. Fluorodopa F 18 Positron Emission Tomography and the Progression of Parkinson Disease